Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
- Author:
Eun Jin HEO
1
;
Young Jae CHO
;
William Chi CHO
;
Ji Eun HONG
;
Hye Kyung JEON
;
Doo Yi OH
;
Yoon La CHOI
;
Sang Yong SONG
;
Jung Joo CHOI
;
Duk Soo BAE
;
Yoo Young LEE
;
Chel Hun CHOI
;
Tae Joong KIM
;
Woong Yang PARK
;
Byoung Gie KIM
;
Jeong Won LEE
Author Information
- Publication Type:Original Article
- Keywords: Patient-derived xenograft model; Subrenal capsule implantation; Ovarian epithelial cancer; Precision medicine; Molecular targeted therapy
- MeSH: Animals; Biology; Cell Line; Drug Therapy, Combination; Eosine Yellowish-(YS); Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Hematoxylin; Heterografts*; Humans; Mice; Microsatellite Repeats; Molecular Targeted Therapy; Ovarian Neoplasms*; Precision Medicine; Translational Medical Research; Tumor Burden
- From:Cancer Research and Treatment 2017;49(4):915-926
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Patient-derived tumor xenografts (PDXs) can provide more reliable information about tumor biology than cell line models. We developed PDXs for epithelial ovarian cancer (EOC) that have histopathologic and genetic similarities to the primary patient tissues and evaluated their potential for use as a platform for translational EOC research. MATERIALS AND METHODS: We successfully established PDXs by subrenal capsule implantation of primary EOC tissues into female BALB/C-nude mice. The rate of successful PDX engraftment was 48.8% (22/45 cases). Hematoxylin and eosin staining and short tandem repeat analysis showed histopathological and genetic similarity between the PDX and primary patient tissues. RESULTS: Patients whose tumors were successfully engrafted in mice had significantly inferior overall survival when compared with those whose tumors failed to engraft (p=0.040). In preclinical tests of this model, we found that paclitaxel-carboplatin combination chemotherapy significantly deceased tumor weight in PDXs compared with the control treatment (p=0.013). Moreover, erlotinib treatment significantly decreased tumor weight in epidermal growth factor receptor–overexpressing PDX with clear cell histology (p=0.023). CONCLUSION: PDXs for EOC with histopathological and genetic stability can be efficiently developed by subrenal capsule implantation and have the potential to provide a promising platform for future translational research and precision medicine for EOC.
